STATISTICS IN MEDICINE VOL. 16, 2941–2943 (1996)

AUTHOR INDEX

Aalen, O. O., 2191
ACSF Investigators, 397
Agresti, A., 2599
Aickin, M., 1845
Akazawa, K., 583
Andersen, P. K., 215
Anderson, S., 441
Ashby, D., 1413
Austin, H., 1005

Bacchetti, P., 645
Bailey, N. T. J., 2447
Barai, U., 941
Becher, H., 993
Becker, N. G., 2339
B,lisle, P., 769
Benichou, J., 133
Bennett, C. L., 1451
Bernardinelli, L., 741
Best, N. G., 741
Betensky, R. A., 465, 2429, 2587
Biggerstaff, B. J., 753
Biscay, R., 1745
Bixler, E. O., 1995
Bjorling, L. E., 1175
Blood, J., 681
Bois, F. Y., 441
Boyett, J. M., 2095
Brant, L. J., 2475
Brenner, H., 981
Breslow, N. E., 103
Brettle, R. P., 2459
Brittain, E., 681
Broemeling, L. D., 321
Brookmeyer, R., 1983
Brown, B. W., 2511
Brown, E. B., 803
Bull, K., 1041
Bull, S. B., 545
Byrne, C., 133

Cai, J., 2009
Capocaccia, R., 425
Carey, V. J., 1667
Carroll, R. J., 169
Carter-Campbell, S., 695
Catalano, P. J., 883
Chen, L., 1167
Chen, R., 1401, 1873
Chow, S.-C., 1031
Chuang-Stein, C., 2599
Clark, I., 1745
Clark, L. C., 853
Cnaan, A., 2349
Commenges, D., 1283
Connelly, R. R., 1401
Cook, P., 321
Cook, R. J., 911
Coste, J., 561
Couper, D., 1551
Crichton, N. J., 717
Cui, J.-S., 2339
Cuzick, J., 1017

Dain, B., 1943
Daniels, M. J., 1965, 2311
Dartiques, J., 1283
Davidian, M., 1765
Davis, C. E., 2009
Day, N. E., 2191
De Angelis, D., 2191
De Angelis, R., 425
De Gruttola, V., 1515
Dear, K. B. G., 2177
Deville, J.-C., 397
Dey, D. K., 1817
Diehr, P., 1211
Dobson, A. J., 2177
Donner, A., 1097, 1753
Drescher, K., 117
Du Berger, R., 769
Dubey, S. D., 2529
Dunnett, C. W., 2489
Dunstan, F. J., 1481
Dyba, T., 2297

Edwards, R., 1017
Eliasziw, M., 1097
Elswick, R. K., Jr., 1695
Erkanli, A., 1121
Etzioni, R., 627

Fairclough, D. L., 1197
Faraggi, D., 2573
Farewell, V. T., 2191
Fatti, L. P., 333
Fay, M. P., 791, 2389
Fayers, P. M., 1413
Feuer, E. J., 791, 2389
Fick, G. H., 373, 2103
Finkelstein, D. M., 951
Fleming, T. R., 1515
Fuerst, T. P., 1889

Gail, M., 133
Gamel, J. W., 1629
Gao, S., 783, 2049, 2419
Gatsonis, C., 2311
Gee, L., 441
Gefeller, O., 981, 1107
Genant, H. K., 1889
Gilks, W. R., 741
Gill, O. N., 2191
Gill, R., 39
Glidden, D. V., 833
Glynn, R. J., 357
Goldberg, R., 1311
Goldbourt, U., 1873
Gonin, R., 1925
Gordon-Salant, S., 2475
Gore, S. M., 2459
Gray, J. C., 1481
Greenland, S., 515
Greenwood, C. M. T., 545
Grill, S. E., 2245
Gu, C., 1357

Haber, M., 601
Hadgu, A., 1391, 2403
Hakulinen, T., 2297
Hall, W. J., 2143
Halpern, J., 153
Hamilton, S. A., 2029
Hanrahan, J. P., 1603
Hardy, R. J., 2063
Hashemi, L., 1311
Hauck, W. W., 441, 545, 1683
Heijde, D. van der, 1653
Heinze, G., 73
Heitjan, D. F., 347, 1791
Hinde, J. P., 717
Hodges, J. S., 1175
Hogan, J. W., 239, 259
Holubkov, R., 103
Hosmer, D. W., 965
Hosmer, T., 965
Hughes, M. D., 865, 1965
Hui, S., 1889
Hui, S. L., 2419
Huque, M. F., 2529
Hyslop, T., 441

Iscovich, J., 1873
Iyer, H. K., 803

Jacqmin-Gadda, H., 1283
Jereb, J. A., 485
Jiang, W., 853
Jim,nez, J. C., 1745
Johnson, W. D., 1081, 2127
Jones, B., 1955
Joseph, L., 769

Kaiser, M. S., 1151
Keiding, N., 215, 273
Klar, N., 1753
Klein, B., 1357
Klein, J. P., 215
Klein, R., 1357
Klerk, E. de, 1653
Knapp, R. G., 1705
Koch, G., 2403
Küchenhoff, H., 169
Kuha, J., 189

Lachin, J. M., 653
Lagakos, S. W., 925
Laird, N. M., 239, 259, 2349
Langer, S. F. J., 1617
Larose, D. T., 1817
Laska, E. M., 2211
Lau, T. S., 2283
Launer, C. A., 1943
Lawless, J. F., 911
Lazaridis, E. N., 1925
Le Cessie, S., 965
Leblond, L., 203
Lee, A. J., 1377
Lee, S. Y., 1859
Lee, W.-C., 729
Leisenring, W., 1263
Lele, C., 2543
Lellouch, J., 397
Lemeshow, S., 965
Li, Q. H., 925
Li, Y., 2095
Lin, D. Y., 901, 1515
Linden, S. van der, 1653
Lindsey, J. K., 1955
Liu, Q., 711(L), 2095
Longton, G., 1263
Love, E. J., 2103
Lu, Y., 1889
Lui, K.-J., 1777

McClish, D. K., 1529
McKee, L. J., 1683
Mackenzie, G., 1831
McMurchy, L., 1377
McNeil, A. J., 2555
McShane, L. M., 1337
Mantel, N., 1401
Marchini, J., 717
Marshall, R., 2022(L)
Martin, D. O., 1005
Martinussen, T., 273
Mathews, J. N. S., 705
Mathur, A. K., 1889
Matsuyama, Y., 1587
Matts, J. P., 1943
May, W. L., 1081, 2127
Mehrotra, D. V., 1465
Meier, K. L., 1337
Meisner, M., 2211
Messiah, A., 397
Meyer, L., 397
Mian, I. U. H., 1497
Miller, C., 1943
Milner, P. C., 2117
Morrell, C. H., 2475
Moy,, L. A., 2267

Nakamura, T., 583
Nandram, B., 1311
Neely Atkinson, E., 1803
Nejjari, C., 1283
Nelson, E. T., 1943
Neuh„user, M., 993
Ng'andu, N. H., 611
Nix, A. B. J., 1481

Obuchowski, N. A., 1529
Ohashi, Y., 1587

Päivärinta, L., 2297
Palensky, J., 681
Palesch, Y., 583
Pan, G., 1645
Park, T., 1859
Parmar, M. B., 1413
Pascutto, C., 741
Patrick, D. L., 1211
Pearson, J. D., 2475
Pepe, M., 5
Pepe, M. S., 1263, 1551
Perkins, L. L., 1005
Pichlmeier, U., 1107
Pitard, A., 527
Psaty, B. M., 1211
Puterman, M. L., 2177
Pyke, S. D. M., 2063

Quan, H., 1225

Reilly, M., 5
Reynolds, T., 1481
Richardson, S., 203
Ritov, Y., 285
Robins, J., 81
Robins, J. M., 21, 39, 285
Roe, D. J., 1241
Rogerson, P. A., 2081
Romano, P. S., 1301(L)
Romanowski, B., 2103
Rose, M. S., 373, 2103
Rosenberger, W. F., 2245
Rosner, B., 357
Rotnitzky, A., 81
Russek-Cohen, E., 455
Russell, K., 2511

Sankoh, A. J., 2529
Schemper, M., 73
Schill, W., 117
Schmoor, C., 225
Schoenfeld, D. A., 951
Schumacher, M., 225
Schwartz, P. F., 1695
Scott, A. J., 1377
Seaman, S. R., 2459
Segal, M. R., 1603
Segnan, N., 1017
Senn, S., 1303(L), 2021(L)
Shao, J., 1031, 1167
Shapiro, D. E., 2143
Sharma, D., 347
Shen, Y., 627
Shih, W. J., 1225, 1913
Shoukri, M. M., 1497
Siev, D., 1151
Simon, R., 2573
Simon, R. M., 455
Slasor, P., 2349
Smith, P. J., 485
Soltysik, R. C., 1451
Soyer, R., 1121
Spiegelhalter, D. J., 1041
Sposto, R., 695
Stablein, D., 695
Stamenovic, E., 951
Stangl, D., 1121
Strömberg, U., 2327
Sun, J., 497

Tager, I. B., 1603
Tamhane, A. C., 2489
Tang, D.-I., 2211
Tango, T., 2621(L)
Ten Have, T. R., 1995
Teoh, N., 941
Terry Beirn Community Programs for Clinical Research on AIDS, 1943
Therneau, T. M., 2029
Thompson, M. L., 333
Thompson, S. G., 2063
Thompson, T. J., 485
Tibshirani, R., 385
Tierney, C., 2587
Torrance-Rynard, V. L., 2157
Tretli, S., 1435
Turnbull, B. W., 853

Turner, B. J., 1683
Tweedie, R. L., 753

Umbach, D. M., 1731
Urquhart, J., 1653

Vacek, P. M., 505
Vach, W., 57
Varga, P., 821(L)
Venot, A., 561
Viel, J. F., 527
Vogel, R. L., 1629
Voit, E. O., 1705
Vuorinen, J., 2229

Wahba, G., 1357
Wakefield, J., 1135
Walker, S., 1135
Wallenstein, S., 1329
Walsh, S. J., 669
Walter, E., 561
Walter, S. D., 2157
Wang, C. M., 803
Wang, Y., 1357
Warszawski, J., 397
Wasserman, D., 561
Wassermann, E. M., 1337
Wei, L. J., 571, 833
Weinberg, C. R., 1731
Welsh, J. A., 1695
Westrom, L., 2403
White, I. R., 2619(L)
Whittemore, A. S., 153, 2543
Wight, S., 1603
Wittes, J., 681
Wolfe, D. A., 1645
Xie, T., 1845
Xue, X., 1983

Yarnold, P. R., 1451
Ye, K., 1889

Zackin, R., 571
Zahl, P.-H., 1435, 1573
Zeng, Q., 1765
Zhao, P.-L., 1913
Zhou, H., 1301(L), 2009
Zhou, X., 783
Zhou, X.-H., 2049
Zou, K. H., 2143

STATISTICS IN MEDICINE, VOL. 16, 2945–2962 (1997)

SUBJECT INDEX*

Notes: Single page numbers refer to individual papers. The page ranges shown indicate collections of papers on particular subjects. (L) after some page numbers identifies letters.

Accident and emergency
  forecasting models, 2117
  longitudinal study, 2928
Accrual buffers, 1925
Accuracy
  clinical trials, 705
  indices ROC curves, 1529
Adenomatous polyps, 1845
Adjustment
  multiple endpoints, 2529
Age
  breast cancer, 133, 1435
  data-dependent interval partition, 1617
Age-specific rates
  reference intervals, 2785
AIDS (Acquired immunodeficiency syndrome)
  see also CD4 lymphocyte counts; HIV
  asymptotic period, 627
  clinical trials
    endpoint, 951, 1175
    surrogate markers, 1515, 1965
  cumulative incidence function, 901
  delay data, 2339
  follow-up losses, 1943
  incidence, 645
  longitudinal studies, smooth curves, 2429
  Markov model analysis, 2191
  pneumonia, 1451
Air pollution, 2928
Alcoholism
  diagnosis test, 1695
Algorithms
  see also Expectation maximization algorithm; Markov Chain Monte Carlo algorithm
  CODA, 285
  LABROC4, 2143
  Metropolis-Hasting algorithm, 1817
  ROC & ROL, 2143
Allocation ratio sample size calculation, 2805
Almon's method, 527
Analysis of variance
  F tests, 2729
  intraclass correlations, 1497
  smoothing spline methods, 1357
Anderson-Gill model, 2029
Anginal attacks, 1955
Antigens, 1151
  non-parallel immunoassay curves, 1151
Antiretroviral therapy
  rule-based ranking schemes, 1175
ARIMA *see* Autoregressive integrated moving averages
Artherosclerosis *see* Coronary artery disease
Assays
  cell dilution, 571
Association
  continuously monitored strategy, 1925
Asthma
  treatment divergence, 2855
Asymptotic confidence intervals, 1329
Asymptotic relative efficiency, 117
Attributable risk
  Bayesian inference, 1311
  epidemiology, 729
  recurrent disease events, 1107
  risk factor prevalence, 2543
Autoregressive integrated moving average models
  accident and emergency attendances, 2117
  reparametrization, 1745

Backcalculation
  HIV diagnosis, 2191
Baseline measurements
  biased baseline rates, 1401
  heterogeneity, 2883
Bayesian inference
  autocorrelated errors, 321
  binomial proportions, 1311

* Compiled by INDEXING SPECIALISTS, 202 Church Road, Hove, East Sussex, BN3 2DJ, U.K.

Bayesian inference (*cont.*)
CODA asymptotic theory, 285
dose determination, 1135
hierarchical models
disease maps, 741
variability analysis, 2311
immunological progression rates, 2555
independence models, chest pain diagnosis, 717
measurement errors, 203
meta-analysis, 1817
persuasion probability, 1791
proportional hazards model, 2573
sample sizes, 769
treatment evaluation, 1803
two-phase prevalence studies, 1121
underlying risk, 2741
Bayesian monitoring scheme
interim analysis, 1413
Bayes'theorem, 1413
Beta-binomial model, 2849
Bias
baseline rates, 1401
cutpoint model, 2813
diagnostic tests, 1391
measurement error, 169
model misspecification, 669
observational studies, 1041
reduction, 545
Binary response
correlated data, 1081, 2127
double-blind clinical trials, 1913
mixed effects models, 1587
randomized clinical trials, 1017
recurrent disease events, 1107
teratologic studies, 2843
two-stage data, 103
Binary screening tests, 2282
Binormal model ROC analysis, 669
Bioassays
non parallel dose-response curves, 1151
Bioavailability
bioequivalence, 803, 2229
replicate crossover designs, 1031
Biochemical markers, 1481
Bioequivalence
higher-order cross-over designs, 1031, 2229
individual, 803
population, 441
Biographies
Semmelweis, I. P., 2767
Biostatistics
future trends, 2773
Birthweight
logistic regression model, 965
maternal smoking, 1603
Bivariate data
discriminant analysis, 2679
power approximation, 865
Bladder cancer, 865
Blinded subjective ranking
treatment effect, 681
Blood pressure
intraclass correlations, 1497
missing data, 2713
BMDP computer package
mixed models, 2349
Bone marrow
transplants
busulfan concentrations, 2095
continuous monitoring, 1925
graft-versus-host disease, 1551
Bone mineral density, 1889
Book reviews
Agresti, A., *An Introduction to Categorical Data Analysis*, 2383
Arminger, G., Clogg, C. C. and Sobel, M. E., *Handbook of Statistical Modeling for the Social and Behavioural Sciences*, 1433
Armitage, P. and David, H. A., *Advances in Biometry*, 2137
Baker, F. B., *Item Response Theory. Parameter Estimation Techniques*, 2261
Bell, F. D., *Basic Statistics: Concepts for the Health Sciences: The Almost No Math Stats Book*, 1307
Beolchi, L. and Kuhn, M. H., *Medical Imaging-Analysis of Multimodality 2D/3D Image*, 2630
Berry, D. A. and Stangl, D. K., *Bayesian Biostatistics*, 1655
Bishop, C. M., *Neural Networks for Pattern Recognition*, 2385
Blond, M., *An Introduction to Medical Statistics*, 2262
Bowers, D., *Statistics from Scratch: An Introduction for Health Care Professionals*, 2932
Breen, R., *Regression Models: Censored, Sample-Selected, or Truncated Data*, 1789
Buncher, C. R. and Tsay, J. Y., *Statistics in the Pharmaceutical Industry (2nd edn)*, 1909
Busby, C., *Wings of Death: Nuclear Pollution and Human Health*, 2025
Campbell, M. J. and Swinscow, T. D. V., *Statistics at Square One*, 2629
Carroll, R. J., Ruppert, D. and Stefanski, L. A., *Measurement Error in Nonlinear Models*, 2628
Chalmers, I. and Altman, D. G., *Systematic Review*, 2929
Chatfield, C., *The Analysis of Time Series - An Introduction*, 2386
Cleveland, W. S., *The Elemants of Graphing Data*, 481
Clogg, C. C. and Shihadeh, E. S., *Statistical*

Models for Ordinal Variables. Advanced Quantitative Techniques in the Social Sciences 4483
Coggon, D., *Statistics in Clinical Practice*, 1193
Cooper, H. and Hedges, L. V., *The Handbook of Research Synthesis*, 713
Corter, J. E., *Tree Models of Similarity and Association*, 1546
Di Rienzo, M., Mancia, G., Parati, G., Pedotti, A. and Zanchetti, A., *Computer Analysis of Cardiovascular Signals*, 1195
Eerola, M., *Probabilistic Causality in Longitudinal Studies*, 2761
Esteve, J., Benhamou, E. and Raymond, L., *Statistical Methods in Cancer Research. Vol IV. Descriptive Epidemiology*, 715
Everitt, B. S., *The Cambridge Dictionary of Statistics in the Medical Sciences*, 1910
Feinstein, A. R., *Multivariate Analysis: An Introduction*, 2382
Finkel, S. E., *Causal Analysis with Panel Data*, 1547
Fischer, G. H. and Molenaar, I. W., *Rasch Models. Foundations, Recent Developments and Applications*, 1431
Forthofer, R. N. and Lee, E. S., *Introduction to Biostatistics. A Guide to Design, Analysis, and Discovery*, 1075
Gäbler, E., *Biometrische Methodik Pharmakologischer Tierexperimente*, 2139
Glasbey, C. A. and Horgan, G. W., *Image Analysis for the Biological Sciences*, 2759
Goldstein, H., *Multilevel Statistical Models (2nd edn)*, 1309
Grayson, Lesley, *Scientific Deception: An Overview and Guide to the literature of Misconduct and Fraud in Scientific Research*, 599
Greenwood, P. E. and Nikulin, M. S., *A Guide to Chi-squared Testing*, 2263
Haccou, P. and Meelis, E., *Statistical Analysis of Behavioural Data - An Approach Based on Time-structured Models*, 1079
Hampton, R. E., *Introductory Biological Statistics*, 1308
Hand, D. and Crowder, M., *Practical Longitudinal Data Analysis*, 2026
Hayduk, L. A., *LISREL - Issues, Debates, and Strategies*, 1911
Hill, C., Com-Nougué, C., Kramar, A., Moreau, T., O'Quigley, J., Senoussi, R. and Chastang, C., *Analyse Statistique des Données de Survie*, 1550
Hoch, J. C. and Stern, A. S., *NMR Data Processing*, 2935
Isham, V. and Medley, G., *Models for Infectious Human Diseases: Their Structure and Relation to Data*, 1545
Kleinbaum, D. G., *Survival Analysis: A Self-Learning Text*, 2934
Knapp, T. R., *Learning Statistics Through Playing Cards*, 1543
Kreienbrock, L. and Schach, S., *Epidemiologische Methoden*, 829
Krzanowski, W. J., *Recent Advances in Descriptive Multivariate Analysis*, 1787
Lange, N., Ryan, L., Billard, L., Brillinger, D., Conquest, L. and Greenhouse, J., *Case Studies in Biometry*, 963
Lehtonen, R. and Pahkinen, E. J., *Practical Methods for Design and Analysis of Complex Surveys*, 482
McNeil, D., *Epidemiological Research Methods*, 2381
Manton, K.G., Woodbury, M. A. and Tolley, H.D., *Statistical Applications Using Fuzzy Sets*, 1789
Marubini, E. and Valsecchi, M. G., *Analysing Survival Data from Clinical Trials and Observational Studies*, 2138
Matthews, J. R., *Quantification and the Quest for Medical Certainty*, 1908
Meinert, C. L., *Clinical Trials Dictionary: Terminology and Usage Recommendations*, 1911
Mollison, D. (ed), *Epidemic Models: Their Structure and Relation to Data*, 1666
Moore, T. J., *Deadly Medicine: Why Tens of Thousands of Patients Died in America's Worst Drug Disaster*, 2507
O'Hagan, A., *Kendall's Advanced Theory of Statistics. Volume 2B*, 1907
Paling, J., *Up To Your Armpits in Alligators? How To Sort Out What Risks Are Worth Worrying About!*, 2929
Parmar, M. B. K. and Machin, D., *Survival Analysis: A Practical Approach*, 714
Peto, R., Lopez, A. D., Boreham, J., Thun, M. and Heath, C. Jr., *Mortality from Smoking in Developed Countries*, 1544
Rasch, D., Tiku, M. L. and Sumpf, D., *Elsevier's Dictionary of Biometry*, 1080
Rees, D. G., *Essential Statistics for Medical Practice - A Case-Study Approach*, 1194
Selvin, Steve, *Practical Biostatistical Methods*, 600
Sloan, M. D., *Using Designed Experiments to Shrink Health Care Costs*, 2627
Stapleton, J. H., *Linear Statistical Models*, 1076
Strike, P., *MEDSAP. A Statistical Toolkit for Health Professionals Version 2*2265
Thall, P., *Recent Advances in Clinical Trial Design and Analysis*, 1077
Utts, J. M., *Seeing Through Statistics*, 2931
Venables, W. N. and Ripley, B. D., *Modern Applied Statistics with S-PLUS*, 1548

Book reviews (*cont.*)
Verma, B. L., Shukla, G. D. and Srivastava, R. N., *Biostatistics: Perspectives in Health Care Research and Practice*, 825
Viertl, R., *Statistical Methods for Non-Precise Data*, 1194
Wallgren, A., Wallgren, B., Persson, R., Jorner, U. and Haaland, J-A., *Graphing Statistics and Data*, 2760
Weir, B. S., *Human Identification: The Use of DNA Markers*, 828
Bootstrap
directly standardized rates, 791
log-normal means, 783
resampling technique, 2813
Breast cancer
asymptomatic period, 627
chemotherapy trials, 1629
DNA flow cytometry, 2813
exposure-specific rates, 133
long-term survival, 1435
prognostic markers, 2573
quality of life analysis, 1197
radiation effect, 21, 39
Breast implants, 1005
British Family Heart study, 2063
Bronchitis
dust concentration, 169
BUGS computer package, 2741
Burkitt's lymphoma, 2081

CABG *see* Coronary artery bypass grafting
Calcium level, 1587
Calibration
comparative study, 1889
immunoassay curves, 1765
CAN *see* Consistent and asymptotically normal...
Cancer
see also Breast cancer
asymptomatic period, 627
Bayesian interim analyses, 1791
case-control studies, 993
data monitoring, 1413
incidence prediction, 2297
mortality, occupational, 505, 515
phase III clinical trials, 1845
prevalence, 425
quality of life assessment, 1197
survival analysis, excess hazards, 1573
three-stage designs, 2701
Canonical systems, 1705
Cardiac data processing, 1617
Cardiology
variability analysis, 2311
Cardiovascular diseases
clinical trials, 2267
risk, frailty model, 1983
risk factors, 1983
Carryover effects
replicate crossover designs, 1031
CART *see* Classification and regression tree...
Case-control studies
colorectal cancer, 1845
data re-using, 1377
early stopping, 2327
genotype/exposure independence, 1731
meta-analysis, 1005
post-hoc stratification, 993
relative attributable risk, 2543
two-stage methods, 103, 117, 133
Categorical data
latent variable model, 883
CD4 lymphocyte counts
see also AIDS; HIV
HIV, marker, 1965
pre-AIDS mortality, 2459
progression rates, 2555
Centile estimates
multivariate approach, 333
Change-score analysis, 1211
Chemotherapy
chemoimmunotherapy trial, 11803
survival analysis, 1629
Chest conditions
pain diagnosis, 717
Chlamydia trachomatis, 1391
Cholesterol
repeated measurements analysis, 653
Chronic diseases
non-fatal recurrent events, 1831
recurrent/terminating events, 911, 925
Classification
method comparison studies, 705
optimal discriminant analysis, 561, 1451
Classification and regression tree (CART) technique, 717
Classification tree analysis (CTA), 1451
Clinical trials
see also Randomization; Stopping rules
AIDS, failure time, 951
Bayesian analysis, monitoring, 1413
binary response studies, 1913
contamination, 1017
continuous monitoring strategy, 1925
data monitoring, 1413
drop-outs, treatment comparison, 1225
endpoints study, 1175, 1197, 2267
follow-up losses, 1943
health status, 1197, 1211
heterogeneity, 583, 2009
HIV, recurrent/terminating events, 925
incomplete covariate data workshop, 1–319
interval-censored data, 497
losses to follow-up, 1943
multiple endpoints, 2529
multiple events data, 833–951

multivariate time-to-event data, 865
phase II
Bayesian interim analysis, 1791
three-stage design, 2701
stopping rules, 465, 1925
treatment efficacy, 1017
treatment interaction, 1645
Cluster analysis
bivariate model, 883
leukaemia, 1873
naturally ordered individuals, 1617
teratologic studies, 2843
Cluster randomization
community interaction trials, 1753
mean hazard ratio parameters, 2009
meta-analysis, 2063
CODA *see* Curse of dimensionality...
Cohort studies
two-stage sampling, 133
Collinearity
pollutants/climatic conditions, 527
Colorectal cancer
adenomatous polyps ocurrence, 1845
Combination
across study designs, 1005
treatments, 2211
Community interventions
pair-matched design, 1753
Community Programs for Clinical Research on AIDS, 1175
Comparative calibration model, 1889
Comparative studies
binomial probabilities, 1329
discordant classification, 705
dropouts, 1225
goodness-of-fit tests, 965
proportional hazards assesment, 611
quality of life trials, 1197
sets/cuscore techniques, 1401
spatial prediction techniques, 1337
treatment effects, 1645
variance components estimators, 1465
Competing risks
cumulative incidence functions, 901
mortality, multivariate data, 951
Complete cases
estimates, 57
Complex survey data, 2419
Compliance
drug dosing histories, 1653
randomized clinical trials, 1017
Computer packages
see also SAS...
goodness-of-fit, 965
MEMS, 1653
multivariate failure time data, 2049
NONMEM, 1135, 1241
SPSS-PC, 1041
Computers
correlated data analysis, 2349
observational studies, 1667
Conditional models
ectopic pregnancy, 2403
measurement errors, 203
Conditional power calculations, 465
Confidence intervals
binomial proportions, 1329
correlated proportions, 2127
directly standardized rates, 791
first event ocurrence, 711–712(L)
log-normal means, 783
longitudinal studies, 2429
qualitative interaction test, 1645
quality performance index, 1301–1303(L)
treatment evaluation, 1017
vital rates, 2389
Confounders
logistic regression model, 993
Confounding
attributable risk, 1107
Connective tissue disease, 1005
Consistent and asymptotically normal estimators (CAN), 81
Contamination
fish, 2327
soils, 1167
Continence status, 1859
Contingency tables
dose-response studies, 2599
Continuation ratio model
ordinal responses, 2873
Continuity correction
confidence intervals, 1329
exact equivalence tests, 1777
Yates', 1329
Continuous confounders case-control studies, 993
Continuous data
multivariate analysis, 883
sample size, 2805
Continuous exposures, 729
Continuous monitoring, 1925
Coronary artery bypass grafting (CABG), 2645, 2829
Coronary artery disease
statistical models, 2829
Corrections
multiple testing, 2511, 2529
Corrections to published papers, 479, 480, 1299–1300, 2927–8
Correlated frailty model, 1573
Correlations
binomial proportions, 1081, 1587, 2127
generalized linear mixed model, 2349
geographical distribution, 1283
intraclass coefficient, 821–823(L)
measurement errors, 2177

Cortical maps, 1337
Counting process
  recurrent event analysis, 2029
Covariates
  incomplete data
    drop-outs, 239, 259, 273
    hot-deck multiple imputation, 5
    measurement errors, 169, 189, 203, 741, 853
    multi-stage studies, 153
    non-response models, 21, 39, 81
    prognostic factors, 57, 73, 225
    two-stage studies, 103, 117
  logistic regression, 1695
  missing values, complex survey data, 2419
  multivariate failure time data, 2049
Coverage probability
  continuity correction, 1329
  mean confidence intervals, 783
Cox proportional hazards model
  see also Non-proportional hazards model
  canonical system derivation, 1705
  confidence intervals, 783
  heterogeneity, 583
  incomplete covariate data, 21, 73, 225
  multiple event data, 951
  multivariate failure time, 833
  multivariate time-to-event data, 865
  proportional hazards assumption, 611, 1831
  surrogate marker, 1515
  variable selection, 385
CPCRA *see* Community Programs for Clinical Research on AIDS
Cross-validation
  cutpoint model, 2813
Crossover trials
  bioequivalence study, 803
  higher-order designs, 2229
  phase III, 2021–2022(L)
  treatment comparisons, 1031
  treatment-patient interactions, 1955
CTA *see* Classification tree analysis
Cumulative incidence
  AIDS, 2459
  competing risks, 901
Cumulative meta-analyses, 2901
Cumulative sum method
  surveillance, spatial patterns, 2081
Curse of dimensionality appropiate (CODA)
    asymptotic theory, 285
Cuscore technique
  biased baseline rates, 1401
Cytomegalovirus disease, 1263

Data augmentation, 189, 653
Data collection
  clustering, 357
  failure time, 215, 259, 497, 833, 841
  follow-up data, 2773
  interval censoring, 485, 497
  longitudinal, 239, 259, 273, 2429
  net-work based mapping, 1667
  skewness, 2785
  survival analysis, 1629
  validation, 189, 203
Data monitoring committees (DMCs)
  interim analyses, 1413
Data re-using, 1377
Decision thesholds, 669
Delay distribution, 2339
Dementia studies, 2419
Depression
  prevalence in adolescents, 1121
Designs
  see also Two-stage design
  paired cluster randomization, 2063
  phase II trials, 2701
  tolerance intervals, 803
Detection rates screening, 1481
Developmental toxicity studies, 883
Diabetes
  cortical cataract, 357
  disease mapping, 741
  retinopathy, risk factors, 1357
Diagnosis
  AIDS, Markov model, 2191
  alcoholism, 1695
  CART methodology, 717
  clustering, 1873
  tests
    accuracy, 1529
    bias effect, 1391
    dependent errors, 2157
    disease, prevalence estimation, 981
    marginal regression model, 1263
    model misspecification, 669
    ROC curves, 2143
Diet
  risk factors reduction, 2127
Directly standardized rates, 791
Discrepant analysis, 1391
Discrete time survival data, 1983
Discriminant analysis
  classification tree analysis, 1451
  ordinal responses, 561
  sum of binary variables, 2679
Diseases
  mapping, 741, 2773
DNA
  amplification tests, 1391
  U.S. blacks genes, 153
Dose
  data analysis, 1653
Dose-response
  initial dose selection, 1135
  non-parallel immunoassay curves, 1151
  ordinal responses, 2599

Double-blind clinical trials, 1913
Down's syndrome
  screening, 1481
Drop-outs
  see also Incomplete data; Missing data
  longitudinal studies, 239, 259, 273
  treatment comparison, 1225
Drugs
  bioequivalence, 441, 803
  carry-over effects, 1031
  compliance assesment, 1653
  dose-response relationship, 1135
  pharmacokinetic modelling, 1241
  shelf-life estimation, 1167
Dual X-ray absorptiometry scanners, 1889
Dynamical disease model, 1705
Dyspnoea
  geographical correlation, 1283

Ectopic pregnancy, 2403
Edinburgh City Hospital HIV Cohort, 2459
EEG *see* Electroencefalography
Efficiency
  combination drug treatment, 2211
  multi-stage sampling, 153
  sets/cuscore techniques, 1401
  surrogate marker, 1515
  treatments, 466, 1803
Electroencephalogram
  spectral methods, 1745
Electronic medication event monitoring method, 1653
ELISA test, 1151, 1765
EM algorithm *see* Expectation maximization...
Emergency room visits longitudinal study, 2928
Empirically penalized quasi-likelihood, 515
Endpoints
  antiretroviral trials, 1175
  event rate uncertainty, 2267
  quality of life, 1197
  surrogate markers, 1515, 1965
Epidemiology
  Bayesian inference, binomial proportions, 1311
  canonical models, 1705
  case-control studies, early stopping, 2327
  cluster analysis, interval partitions, 1617
  correlations, 2177
  directly standardized rates, 791
  ectopic pregnancy, 2403
  exposure study
    hierarchical models, 515
    intensity effect, 505
    Lorenz curve, 729
    pollutants time series, 527
  generalized linear mixed model, 2349
  genetic, 153
  incomplete covariate data workshop, 1–319
  repeated medical random counts, 1831
  risk
    incidence studies, 1357, 1377
    recurrent disease events, 1107
  vaccination effectiveness, 601
Equivalence tests
  inverse sampling, 1777
  proportion of similar responses, 1303–1306(L)
Error
  see also Measurement error
  autocorrelated, 321
  covariates, 741
  detection rates, 1481
  diagnostic tests, 2157
  disease registries, 2633
Estimating equation
  longitudinal data, 2429
Estimations
  age-specific reference intervals, 2785
  asymptomatic period, 627
  bias reduction, 545
  complex sampling, 397
  correlation parameters, 2177
  data augmentation, 189
  detection rates, 1481
  discrete observation time, 273
  false positive rates, 1481
  genotype-exposure interaction effect, 1731
  heterogeneity, 753
  interobserver variation, 1097
  inverse-probability-weighted equations, 21
  lasso method, 385
  mean hazard ratio parameters, 2009
  multicollinearity, 527
  non-proportional hazards model, 1831
  odds ratio, 993
  prevalence, 425, 1551
  reference intervals, 2785
  sample size, 769
  segmented regression model, 169
  sensory events, 2245
  treatment effects, 225
  two-stage data, 103, 117
  vaccine efficacy, 601
  variance components, 1465
  vital rates overdispersion, 2389
Event rates
  uncertainty, 2267
Event time distribution, 239, 259
Excess hazards, 1573
Expectation maximization algorithm
  asymptomatic period, 627
  incomplete covariate data, 39, 117, 239
Experimental designs
  fully sequential procedure, 2587
  quasi-sequential procedure, 2587
  treatment evaluation, 1803
Exploratory data analysis
  false positive rates, 2095

Exploratory data analysis (*cont.*)
human cortical motor representations, 1337
prognostic factors, 2095
Exposure
case-control studies, 1731
cohort studies, 133
disease risk analysis, 729
intensity, 505
maternal smoking, 1603
recurrent disease events, 1107
temporal clustering, 1873
Exposure-response analysis
lung cancer, 505
Extra-Poisson regression model, 2389

F-distribution, 2805
F-tests
treatments comparison, 2729
Failure time
see also Survival analysis
competing risks, 901
interval-censored data, 497
multiple events data, 833, 841, 925, 951
omitted covariates, 215, 259
False positive rate screening, 1481, 2095
diagnostic tests, 2143, 2157
Fieller's confidence interval, 2229
Finite mixture distribution, 2843
Fisher's transformation, 1745
Fixed time interval, 1041
Foetuses
development, 321
litter effect, 2843
weight, 883
Follow-up studies
accident and emergency, 2117
losses, 1943
meta-analysis, 1005
record linkage errors, 2633
Forecasting
ARIMA model, 2117
Formulation effect bioavailability/bioequivalence, 803
FORTRAN computer program
ROC & ROL algorithm, 2143
Frailty models
discrete time survival data, 1983
excess hazards, 1573
omitted covariates, 215
Framingham Heart Study, 1983
Functional methods *see* Semi-parametric methods

Gamma distribution
confidence intervals, 791
Gender
treatment response, 455
Generalized additive model, 1551
Generalized estimating equation
ectopic pregnancy, 2403
Generalized linear models
immunoassay curves, 1151
interactions, 1955
interval-censored data, 485
mixed model analysis, 2349
residuals correlation, 1283
Generalized Pólya urn model, 2245
Genetics
exposure independence, 1731
multi-stage sampling, 153
Geographical correlations
disease mapping, 741
Gibbs sampling, 203
Bayesian inference, 1121
Bayesian meta-analysis, 1817, 2741
hierarchical polytomous regression models, 2311
mixed effects models, 1587
Gini index, 729
Glaucoma
intraocular pressure, 347
GLIM computer package
incidence prediction models, 2297
Goodness-of-fit
kappa statistic, 1097
logistic regression model, 965
Graft-versus-host disease (GVHD)
prevalence, 1551
Graphical analysis
losses to follow-up, 1943
Great Smoky Mountain Study, 1121
Group sequential methods
monitoring clinical trials, 653
Grouped data
survival analysis models, 695
Grouped random effects model, 1817
Growth factor studies
repeated infections, 941
Growth measurements
longitudinal norms, 2665

Hazards
frailty models, 1573
proportional assumption, 611
Health care
environmental hazards, 485
provider profiling, 2645
Health status, 1197, 1211
Hearing problems, 2475
Heart
relaxation, 1617
Heart disease
enalapril treatment, 2009
sub-population variability, 2177
Height
growth norms, 2665
Hemodialysis, 1587

Heterogeneity
discrete time survival data, 1983
frailty models, 215
meta-analyses, 2741, 2883
multi-stage screening tests, 1995
random effects meta-analysis, 753
treatment effects, 2009
Hierarchical models
epidemiologic analyses, 515
interobserver agreement studies, 1097
polytomous regression model, 2311
Higher-order crossover design, 803, 1031
Highest density region (HDR), 1311
HIV (Human immunodeficiency virus)
see also AIDS; CD4 lymphocyte counts
backcalculation, 2191
immunological progression, 2555
incidence/mortality, 645
incubation, 2447
maternal-child transmission, 1683
pre-AIDS mortality, 2459
recurring/terminating processes, 925
virological measurements, 571
HLA (hystocompatibility antigens), 1925
Homogeneity
intra-run variance parameters, 1765
intraclass correlations, 1497
patient populations, 1803
Horvitz-Thompson estimator, 153, 285
Hosmer-Lemeshow statistic, 965, 981
Hot-deck imputation method, 5
Human cortical motor representations, 1337
Hyperparathyroidism, 1587
Hypertension
blood pressure study, 2713
treatment evaluation, 681
Hypertext
observational studies, 1667
Hypothesis testing
correlated proportions, 2127
treatment effects, 465

IDDM *see* Insulin Dependent Diabetes Mellitus
Immunoassays
ELISA test, 1151
intra-run variation, 1765
Immunological markers HIV indicators, 2555
Imputation methods
missing data, 5, 2713
probability imputation technique (PIT), 73
Incidence
see also Mortality; Rates
AIDS, 645
cancer
exposure-specific rates, 133
prevalence estimates, 425
disease, rates estimation, 1401
risk factors relationship, 1357, 1377
simple non-linear model, 2297
Incomplete data
see also Drop-outs; Missing data
cross-over designs, 1031
delay distribution, 2339
measurement errors, 169, 189, 203
omitted covariates, 215, 225
Incubation period, AIDS
cancer connection, 627
revised assesment, 2447
Index
see also Gini index
equivalence test, 1777
quality performance, 1301–1303(L)
Infection
HIV
incubation period, 2447
multivariate failure models, 951
multiple events data, 941
vaccine efficacy estimation, 601
Inference
see also Bayesian inference
CODA asymptotic theory, 285
complex sampling, 397
cumulative incidence functions, 901
delay distribution, 2339
interobserver agreement studies, 1097
missing values, 81
recurrent events, 911
Instrumental data
gold standard, 1889
Insulin Dependent Diabetes Melitus (IDM), 741
Intention-to-treat
non-compliance, 1017
Interactions
treatment-patient, 1955
two-treatment clinical trial, 1645
Interim analysis
Bayesian inference, 1791
clinical trials monitoring, 1413
sample size re-estimation, 1913
International Society for Clinical Biostatistics meetings, 2767–2929
Internet
observational studies, 1667
Interobserver variation
agreement data analysis, 1097
Interval
censored data
failure time, 497
tuberculosis, 485
estimation
heterogeneity, 753
sample size, 769
partitions, 1617
tolerance, 803
Intra-run variation, 1765

Intraclass correlation
coefficients, 821–823(L)
multiple samples, 1497
Intracluster correlation
pair-matched trials, 1753
Intravenous drug users
pre-AIDS mortality, 2459
Intraventricular blood pressure, 1617
Inverse-probability-weighted estimating equations, 21
Israel
leukaemia, 1873

Jackknife
bias reduced estimates, 545
Joint distribution, 883

Kaplan-Meier survival estimates
competing risks failure time data, 901
HIV maternal-child transmission, 1683
Kappa statistic
observer agreement studies, 1097
Kernel method, 2143
Kidney transplantation
recurrent/terminating events, 911
Kinesthetic stimuli, 2245
Kolmogorov-Smirnov test
cumulative incidence curve, 901
Kriging prediction cluster analysis, 1337

Laguerre polinomials, 2927
Laplacian smoothing splines, 1337
Lasso method
Cox model, 385
Latent class analysis
diagnostic error, 2157
multiple binary screening tests, 2282
Latent variable models, 883
clustered survival data, 2009
Least squares
binomial proportions, 1329
hierarchical regression, 515
Leukaemia
cluster analysis, 1873
Liang-Zeger methodology
ectopic pregnancy, 2403
Likelihood ratio
disease prevalence, 981
population bioequivalence, 441
treatments comparison, 2729
Linear divergence, 2855
Linear logistic models
canonical system description, 1705
Linear models
mixed effects, 1587
mixed-effects, hearing percentiles, 2475
Linear regression models
lack of fit, 373

Litter effects, 2843
Log-normal distribution
mean, 783
mean confidence intervals, 783
Log-normal model
comparative study, 1629
simulated survival data, 1629
Logistic regression model
case-control studies, 993
confidence intervals 1301-1306(L)
covariates transformation, 1695
goodness-of-fit tests, 965
HIV transmission model, 1683
interval-censored data, 497
missing data, 2419
odds ratio, 993, 1695
two-stage sampling, 103, 117
Logrank test statistic
power, 583, 1629
survival study, 695
Longitudinal growth norms, 2665
Longitudinal studies
dropouts, 239, 259, 273
ectopic pregnancy, 2403
foetal development, 321
generalized linear mixed model, 2349
missing data, 1859
repeated-series data, 347
Lorenz curve
Gini index, 729
Lung cancer
toxic agents exposure, 505
Lymphoma
repeated infections, 941

Mcnemar test
correlated proportions, 1081, 2127
Malaria
IDDM association, 741
Mann-Whitney statistic
distribution-free estimators, 653
Mantel-Haenszel statistic
meta-analyses, 1005
sample size requirements, 2927
Manton-Woodbury model, 273
Maps
disease risk, 741, 2773
MAR *see* Missing at random
Marginal models
diagnostic tests, 1263
ectopic pregnancy, 2403
multiple event time data, 841
recurrent event data, 2029
recurrent/terminating events, 911
survival data, 1983
Markov Chain Monte Carlo
Gibbs sampling, 1121, 1587
population models, 1135

Markov model
HIV, 2191
multiple events data, 941
ordinal responses, 2873
treatment comparisons, 941
Maternal
HIV transmission, 1683
weight, 1603
Maximum likelihood
Bayesian inferences comparison, 321
bias correction, 545
case-control studies, 1377
intraclass correlations, 1497
logistic regression, 2419
measurement error models, 169, 189, 853
meta-analysis, 2883
mixture models, 239, 259
prognostic factors, 57
treatment effect, 225
two-stage data, 103, 117
variance components, 1465
Maximum pseudo-likelihood, 2009
Mean hazard ratio parameters, 2009
Mean-score method, 5
Means
complex sampling, 397
Measles
vaccine efficacy estimation, 601
Measurement error
see also Error
correlations, 2177
incomplete covariate data, 169, 189, 203
random effects model, 853
Measurement methods
blood pressure prediction, 2713
centile charts, 333
comparative calibration, 1889
correlated binomial proportions, 1081, 2127
kappa statistic, 1097
virology, 571
Median polish kriging, 1337
Meta-analyses
Bayesian analysis, 1817
cluster randomized trials, 2063
heterogeneity, 2741, 2883
random effects, 753, 1817
sequential trials, 2901, 2915
sparse data, 1005
surrogate markers, 1965
Metropolis-Hasting algorithm, 1817
Minimum obstruction diameters (MOD), 2829
Minimum variance unbiased estimator, 1465
Missing at random (MAR) assumption, 21, 57, 133, 1587
Missing completely at random (MCAR) assumption, 1587, 1859
Missing data
blood pressure measurements, 2713
data augmentation, 189
hot-deck multiple imputation, 5
imputation method, 2713
logistic regression, 2419
mean-score method, 5, 39
non-ignorable, 1587, 2713
non-monotone processes, 21, 39
prognostic factors, 57, 73
two-stage sampling, 103, 117, 133
Mixed effects models
hearing percentiles, 2475
intra-run assay variation, 1765
repeated measures data, 1587
Mixed effects Poisson regression model, 853
Mixed model analysis, 2349
Mixture model
dropouts, 273, 1225
incomplete data, 259
joint distribution, 239
MOD *see* Minimum obstruction diameters
Models
accelerated failure time, 215
autoregressive time series, 1745
binary response, 103
cancer prevalence, 425
chest pain diagnosis, 717
clustered ordinal data, 357
comparative calibration, 1889
conditional, 203
coronary artherosclerosis, 2829
crossover designs, bioequivalence, 803, 2229
cutpoint problem, 2813
drop-outs, 1225
epidemiology, 1705
forecasting, 2117
frailty, 215
gene-environment interaction, 1731
information flow, 1667
interval-censored data, 485
latent variable, 883
maternal weight gain, 1603
misspecification, 669
mixture, 239, 259, 273
oncological data, 2773
ordinal responses, 2873
pharmacokinetics, 1241
population, 1135
population heterogeneity, 1995
provider profiling, 2645
recurrent/terminal events, 911
repeated dichotomous data, 2773
repeated-series longitudinal data, 347
selection, 259
smoothing spline ANOVA, 1357
transient state, 1551
treatment-patient interactions, 1955
Monitoring
biased baseline rates, 1401

Monitoring (*cont.*)
clustering, 1873
drug dosing histories, 1653
partially grouped logrank test, 695
spatial patterns, 2081
stopping boundary methodologies, 1925
Monitoring Trends & Determinants of Cardiovascular Disease, 2177
Monte Carlo simulations
see also Simulations
bioequivalence, 441
incomplete covariate data, 73, 273
interval-censored data, 485
intraclass correlations, 1497
jackknife/Taylor series comparison, 545
missing data, 1859
model selection methods, 2679
multiple test procedures, 2529
ROC curve indices, 1529
variance estimation methods, 1465
Moran's I
geographical correlation, 1283
Mortality
AIDS-related pneumonia, 1451
breast cancer, 1435
cancer, 505, 515
competing risk, 951
endpoints, 1175
excess hazards rate, 1573
post-operative study, 1041
pre-AIDS, 2459
Multi-stage design, 153
Multicentre clinical trials
treatment effect, 2009
Multicentre studies
observational data, 1041
Multicollinearity, 527
Multilevel models
longitudinal growth norms, 2665
Multinomial variables
interobserver agreement studies, 1097
recurrent disease events, 1107
Multiple...
endpoints, 833
adjustment methods, 2529
AIDS trials, 951
cancer trials, 1197
event data, 833–951, 2029
independent diagnostic classifications, 2022–2024(L)
testing
correcting methods, 2511
endpoint adjustment, 2529
new treatment, 2489
population heterogeneity, 1995
tests
drop-outs, 1225
latent class model, 2282
Multiple samples
intraclass correlations, 1497
Multistage models
heterogeneity, 1995
Multivariate data
analysis, 883
centile estimation, 333
clustering, 357
failure time, 833, 841, 951
covariate effects, 2049
recurring/terminating processes, 925
time-to-event data, 865
Muscatine Coronary Risk Factor Study, 1859
Myocardial infarction
gender differences, 1311

Naive analysis, 783, 2741
Neonatal study
audiology screening tests, 1263
New Zealand Cot Death Study, 1377
Non-compliance
randomized clinical trials, 1017
Non-constant variance, 2475
Non-ignorable data, 2713
Non-linear measurement error models, 853
Non-monotone models, 21, 39
Non-parallel immunoassay curves, 1151
Non-parametric saturated processes (NPS), 21
Non-parametric statistics
comparative study, 1629
Non-proportional hazards model, 1831
Non-response models
incomplete covariate data, 21, 39, 81
Non-treponemal tests, 2103
NONMEM computer program, 1135, 1241
Normal distribution
discordant classification, 705
multivariate, 333
treatment effects, 455
Northern Ireland
valvotomy study, 1831
Norway
breast cancer, 1435
NPS *see* Non-parametric saturated processes

O'Brien test, 653
O'Brien-Flemming procedure, 465
meta-analysis, 2915
Observational data
computer systems, 1667
survival analysis, 1041
unequally spaced, 321
Obstructive sleep apnoea, 1995
Occupational...
hazards
exposure intensity, 505
tuberculosis, 485

Ocular hypertension
intraocular pressure, 347
ODA *see* Optimal discriminant analysis
Odds ratio
Bayesian analysis, 1311
case-control studies, 993
logistic regression, 1695
variance, 2927
Optic neuritis, 2729
Optimal designs
phase II cancer trials, 2701
Optimal discriminant analysis (ODA), 561, 1451
Oral clefting, 1731
Ordered response
multivariate analysis, 883
Ordinal data
cluster analysis, 357
Ordinal response
continuation ratio model, 2873
dose-response studies, 2599
optimal discriminant analysis, 561
Ossification study, 2843
Osteoporosis
bone mineral density, 1889
Otitis media, 357
Ovarian cancer
risk factors, 2543
Overdispersion
Poisson models, 2389

P-values
multiple tests, 2511, 2529
Pair-matched designs, 1753
Palmgren model, 1377
Parametric bootstrap method, 783
Parametric methods
comparative study, 1629
incomplete covariate data, 57, 169, 285
measurement errors, 169
population bioequivalence, 441
prevalence, 425
reference intervals, 2785
Partially grouped logrank test, 695
Partitioning methods
data-dependent interval partition, 1617
Patient treatments
classification trees, 717
Pearson's chi squared statistic
logistic regression model, 965
Percentiles
longitudinal data, 2475
Permutation missingness models (PM), 21
Permutation tests
geographical correlation, 1283
Persuasion probabilities, 1791
Pharmacokinetics
Population Modelling Workgroup, 1241
random shelf-lives, 1167
PIT *see* Probability imputation technique
PM *see* Permutation missingness models
Pneumocystis carinii
in-hospital mortality, 1451
multiple events data, 901
Point estimations
intraclass correlations, 1497
Poisson regression model
colorectal polyps ocurrence, 1845
overdispersion, 2389
recurrent events, 853
Polychotomous logistic regression, 545, 2928
Polynomial model
longitudinal data, 2927
Population Modelling Workgroup, 1241
Populations
disease prevalence, 981
disease rates, 2543
exposure-disease association, 729
heterogeneity, 1983
initial dose selection, 1135
subpopulation response, 1803
Post-hoc stratification, 993
Power
correlated binary responses, 1081
model misspecification, 669
multivariate proportional hazards model, 865
qualitative interaction test, 1645
years of healthy life analysis, 1211
Precision
model misspecification, 669
Prediction
AIDS incidence, 2191
human cortical motor representations, 1337
in-hospital mortality, 1451
incidence, 2297
random shelf-lives, 1167
seroreversion, 2103
Predictors *see* Covariates
Pregnancy
developmental toxicity study, 883
Down's syndrome, 1481
maternal smoking, 1603
maternal-child HIV transmission, 1683
weight and fundal height, 333
Premenstrual syndrome, 1031
Prevalence
Bayesian methods, 1121
cancer, 425
chronic graft-versus-host disease, 1551
diseases, 981
Prior distribution
measurement errors, 203
Probability imputation technique (PIT), 73
Prognostic factors
age/clinical stage, 1435
covariates, 2573
false positive rates, 2095

Prognostic factors (*cont.*)
incomplete covariate data, 57, 73, 225
Proportional hazards model
see also Cox proportional. . .
Bayesian statistics, 2573
Proportions
binomial comparisons, 769, 1329
correlations, 2127
Prostate cancer
multi-stage study, 153
probability imputation technique, 73
Provider profiling, 2645
Pseudo-likelihood (PL)
two-stage data, 103, 117, 133
Psychiatry
disorders prevalence, 1121
Public health surveillance
recurrent attributable risk, 1107

Quality of life
cancer clinical trials, 1197
years of healthy life, 1211
Quantiles
stimulus-response curves, 2245
Quasi-likelihood
hierarchical regression, 515

Radiation
therapy, breast cancer, 21, 39
Radiology, 1529
Rainbow test, 373
Random effects model
meta-analysis, 753
recurrent event data, 853
Random effects models
Bayesian meta-analysis, 1817
blood pressure study, 2713
coronary artherosclerosis, 2819
meta-analysis, paired cluster randomization, 2063
Randomization
clinical trials, 1017, 1211, 2619–2621(L)
community intervention studies, 1753
recurrent event data, 853
Randomized monotone missingness model (RMM), 39
Rank tests
antiretroviral trials, 1175
Rates
bias baseline rates, 1401
directly standardized, 791
excess hazards, 1573
immunological progression, 2555
maternal-child HIV transmission, 1683
risk factors, 2543
RAVE estimators, 1465
Receiver operator characteristic curves
binormal model, 669
diagnostic test accuracy, 1529
diagnostic tests, 2143
generalized linear model, 1299
Record linkage, 2633
Recurrence
attributable risk, 1107
non-proportional hazards model, 1831
Recurrent event data
counting process methods, 2029
multi-state failure time, 833, 841
regression models, 853
terminating events dependence, 911
Wei-Lin-Weissfeld method, 925
Reference centiles
age related, 2785
Reference ranges
age-specific intervals, 2785
skewed data, 2785
Registry data
record linkage errors, 2633
Regression
see also Linear. . .; Logistic. . .; Poisson. . .
autocorrelated errors, 321
autoregressive parameters, 1745
diagnostic tests, 1263
hierarchical, 515
interval-censored data, 497
logistic analysis, 103, 117
measurement errors, 169, 189
missing covariate value, 5, 81
omitted covariate, 215, 225
prognostic factors, 57, 73
recurrent event data, 853
survival analysis, heterogeneity, 1983
Regression calibration method, 169
Regression Growth Evaluation Statin Study (REGRESS), 2829
Relative attributable risk, 2543
Relative potency, 1151
Relative risk
adjustment methods, 2543
Bayesian inference, 1311
case-control studies, 1005
exposure-disease association, 729
Relative survival, 425
Reparametrization, 1745
Repeated measurements
distribution-free analyses, 653
generalized linear mixed model, 2349
longitudinal data, 347
measurement errors, 169, 203
mixed efffects models, 1587
mixture models, 239, 259
quality of life, 1211
time-to-event data, 865
treatment effects, 2855
virology, 571
Repeated significance test, 465
Residual confounding, 993

Residuals
correlation test, 1283
correlations, 1283
Response effects
repeated measurements, 1587
RhDNase
recurrent event analysis, 2029
Rhinitis, 2873
Risk/risk factors
see also Attributable risk; Relative risk
adjustment methods, 2645
breast cancer surveillance, 1435
cancer, 1573
community intervention trials, 1753
competing, cumulative incidence function, 901
diet, 2127
disease rates, 2543
exact equivalence test, 1777
exposure factors, 505
Gini index, 729
incidence relationship, 1357, 1377
meta-analysis, 2741
RMM *see* Randomized monotone missingness models
Robust estimators, 1465
Robustness
binormal ROC curves, 669
ROC *see* Receiver operator characteristic curves
Rule-based ranking schemes, 1175

S-System models, 1705
Sample size
Bayesian inference, 769
diagnostic test, accuracy, 1529
endpoint event rates, 2267
estimation issues, 1913
recalculation, 2587
treatment effects, 455
unequal group sizes, 2805
Sampling
inverse, 1777
multi-stage studies, 153
nationwide basis, 397
two-stage studies, 103, 117, 133
validation sample, 189
San Francisco
HIV/AIDS incubation period, 2447
SAS computer package, 753
heterogeneity estimation, 753
interactive management, 1667
mixed models, 2349
NLINMIX, 1241
recurrent event analysis, 2029
SAS computer program
PROC IML, 2127
SBV *see* Sum of binary variables
Schizophrenia, 239
Sclerotherapy trials, 2741
Sclove's estimation, 527
Score statistic
logistic regression model, 965
proportional hazards, 611
Scorecarding *see* Provider profiling
Screening
biochemical markers, 1481
diagnostic tests, 1263
multiple binary tests, 2282
prevalence estimation, 1121
reference intervals, 2785
Selection
models, 2679
Semi-Markov process, 1831
non-proportional hazards model, 1831
Semi-parametric methods
CODA asymptotic theory, 285
measurement error models, 169
missing covariate value, 5, 21, 39
multivariate failure time data, 2049
repeated virological measurements, 571
vital rates variation, 2389
Semivariogram analysis, 347
Sensitivity
completeness index, 425
continuously monitored strategy, 1925
discrepant analysis, 1391
disease prevalence, 981
missing data, 21
multi-stage screening tests, 1995
random effects model, 753
screening methods, 1121, 1263
Sequential clinical trials
meta-analysis, 2901, 2915
stopping rules, null hypothesis, 465
Sequential designs
combined studies, 2901
psychophysical experiments, 2245
Serology
seroreversion, 2103
Sets technique
biased baseline rates, 1401
clustering, 1873
Sexual behaviour
ACSF survey, 397
Shelf-life drug test, 1167
Simple model
incidence prediction, 2297
Simulated clinical data, 1241, 1629
Simulation extrapolation (simex) method, 169
Simulations
see also Monte Carlo simulations
asymptomatic disease, 627
Bayesian proportional hazards, 2573
bias reduction, 2813
confidence intervals
directly standardized rates, 791
log-normal means, 783

Simulations (*cont.*)
correlated binomial proportions, 1081, 2127
correlations study, 1283
FWE and power, 2489
goodness-of-fit, 965
initial dose selection, 1135
lasso method, 385
mean hazard ratio estimators, 2009
missing data, 2713
multivariate failure time data, 2049
multivariate time-to-event data, 865
overdispersion, 2389
partially grouped logrank test, 695
population pharmacokinetics model, 1241
prostate cancer, 153
sample size calculation, 1913
surrogate markers, 1515
tolerance intervals, 803
Single-step test multiple comparisons, 2489
Skin cancer, 853
Slope estimation, 2555
Smoking
birthweight, 1603
genotype/exposure interaction, 1731
Space-time cluster analysis, 2621–2625(L)
Spatial autocorrelation
geographical correlation, 1283
Spatial clustering
surveillance systems, 2081
Spatial data
exploratory analysis, 1337
Special issues
see also Workshops
International Society for Clinical Biostatistics, 2767–2929
Statistical Methods for Incomplete Covariate Data in Clinical and Epidemiological Studies, 1–319
Statistical Methods for Multiple Events Data in Clinical Trials, 833–963
Tutorials in Biostatistics, 1041, 1413, 2349, 2599
Specificity
diagnostic tests, 1263
discrepant analysis, 1391
disease prevalence, 981
multi-stage screening tests, 1995
screening, 1121
Spectral methods, 1745
Spline curves smoothing
see also Laplacian smoothing splines
ANOVA methods, 1357
longitudinal data, 2429
SPSS-PC computer package, 1041
Stability analysis
batch-to-batch variation, 1167
Standardization
rates, confidence intervals, 791
Step-down procedure, 2489
Step-up procedure, 2489
Stimulus-response curves, 2245
Stopping rules
boundaries, 1925
case-control study, 2327
phase II trials, 1791
Stratification
case-control studies, 2327
community intervention trials, 1753
dose-response relations, 2599
odds ratio estimation, 993
Structural methods *see* Parametric methods
Studies of Left Ventricular Dysfunction, 2009
Sum of binary variables (SBV) model selection, 2679
Summary statistics
quality of life, 1197
treatment divergence, 2855
Surrogate endpoint variables
missing values, 57
treatment effects, 1515
Surrogate markers
meta-analysis, 1965
Surveillance
spatial patterns, 2081
Surveys
sexual behaviour, 397
Survival analysis
breast cancer, age/clinical stage, 1435
competing risks, 901
frailty models, 1573
HIV, time-to-diagnosis analysis, 1683
incomplete covariate data, 215, 259
logrank test, grouping of data, 695
multivariate methods, 357
observational studies, 1041
parametric methods, 1629
randomized clinical trials, 2619–2621(L)
record linkage errors, 2633
treatment effects, 455
Susceptible-infectious-recovered (SIR) model, 601
Synergism, 2211
Syphilis
serologic response, 373, 2103
Systolic Hypertension in the Elderly Program, 681

Taylor series
bias reduction, 545
binormal ROC curves, 1529
Teratologic studies, 2843
Terminating event data
recurrent events dependence, 911
Wei-Lin-Weissfeld method, 925
Tests
see also Diagnosis. . .; Multiple. . .
correlated proportions, 1081
DNA-amplification, 1391
dose-response relations, 2599

exact equivalence test, 1777
geographical correlations, 1283
goodness-of-fit, 965
MCAR assumption, 1859
multiplicity corrections, 2511
proportional hazards assesment, 611
superiority/equivalence, 2489
treatments comparison, 1225, 2729
treatments qualitative interaction, 1645
variance parameters homogeneity, 1765
Thall
Simon and Estey (TSE) method, 1925
Three-period crossover design, 1031
Three-stage design, 2701
Threshold analysis
decision theory, 669
measurement errors, 169
Time series analysis
epidemiology, 527
Time-dependent covariates
proportional hazards model, 611
Time-to-diagnosis analysis, 1683
Time-to-event data, 865, 1803
TOHP *see* Trials of Hypertension Prevention
Tolerance
interval, 803
Toxicity evaluation
developmental study, 883
Transformation
covariate vector, 1695
Transmission models
HIV, maternal-child, 1683
Transplantation
bone-marrow, 1551
Treatments
adverse effects, 465
changes, 2619–2621(L)
combination drug efficacy, 2211
comparative studies, 941, 1031, 1225
comparative study, 2729
effects
covariate omission, 225
crossover trials, 1955
endpoint determination, 681
gender homogeneity, 455
heterogeneity, 2883
linear divergence, 2855
mean hazard ratio parameters, 2009
multiple event data, 841
sample size estimation, 1913
surrogate markers, 1515, 1965
underlying risk, 2741
efficacy
multiple event data, 833, 841, 941
non-compliance, 1017
randomized clinical trials, 1017
subpopulation response, 1803
multiple testing, 2489
phase II clinical trials, 2701
qualitative interaction, 1645
response, 373
serologic response, 2103
Tree-based models, 717
Trends
biostatistics, 2773
Trent health district, 2117
Trials of Hypertension Prevention (TOHP), 2713
Triangular test
meta-analysis, 2901, 2915
Truncated Poisson regression model, 1845
Tuberculosis
occupational hazards, 485
Tumours
gynaecology, 1107
Tutorials in biostatistics
Bayesian data monitoring, 1413
dose-response studies, 2599
general linear mixed model, 2349
survival analysis, 1041
Two-group design
optimal sample allocation, 2805
Two-period crossover design
bioequivalence, 2229
Two-stage design
gender response, 455
missing data, 103, 117, 133
prevalence, 1121
sample size, 2587

Uncertainty
endpoint event rates, 2267
United States
colorectal cancer, 1845
HIV, 645
Medicaid data, 1683
Unweighted sum-of-squares test, 965
Urn model, 2245

Vaccines
efficacy, estimation, 601
non-parallel immunoassay curves, 1151
Validation
binary diagnostic tests, 981
covariate measurement errors, 189
losses to follow-up, 1943
multiple binary screening tests, 2282
Valvotomy study, 1831
Variability
analysis, 2311
heterogeneity estimates, 753
Variances
within-subject designs, 1465
Varying-coefficient models, 1603
Viruses
cell dilution assays, 571

Vital rates
  overdispersion, 2389
Vitamins
  A, deficiency, 1107
  D3, hyperparathyroidism, 1587

Wald statistic
  correlated binomial proportions, 1081, 2127
Wei-Lin-Weissfeld method, 925
Weibull distribution
  time-to-diagnosis analysis, 1683
Weight
  growth norms, 2665
  maternal weight gain, 1603
Weighted likelihood
  mean-score method, 5
  two-stage data, 103
Wheat Bran Fibre Study, 1845
Wisconsin Epidemiological Study of Diabetic Retinopathhy, 1357
Within-subject designs, 1465
Worcester Heart Attack Study, 1311
Workshops
  incomplete covariate data, 1–319
  multiple events data, 833–963

Yates' correction
  binomial comparisons, 1329
Years of healthy life, 1211